Clinical Study on the Application of a Non-Invasive Micro-Focused Ultrasound With Visualization System for Skin Laxity (ULT-215)

Facial Skin Laxity Clinical Trial

— ULT-215  

Official title:

Clinical Study on the Application of a Non-Invasive Micro-Focused Ultrasound With Visualization System for Skin Laxity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03545412
• Other study ID #: ULT-215
• Status: Completed
• Phase: N/A
• Start date: January 10, 2014
• Est. completion date: August 20, 2014

Study information

• Verified date: May 2018
• Source: Merz North America, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the effect of the Ulthera® system for facial laxity and sagging skin

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: August 20, 2014
• Est. primary completion date: May 20, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 39 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Willing to sign a written consent form

2. Willing to have of facial skin laxity and wrinkles assessed by clinician

3. Male or female, aged 39 to 65 years.

4. Willingness to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.

5. Willingness to cooperate with photography and adherence to photography procedures (i.e., removal of jewelry and makeup).

6. Must understand the ultrasound device (Ulthera) treatment may have no therapeutic effect.

7. Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure.

Exclusion Criteria:

1. Open wounds or lesions in the area(s) to be treated.

2. Severe or cystic acne on the area(s) to be treated.

3. Presence of an active systemic or local skin disease that may affect wound healing.

4. Active implants (e.g., pacemakers or defibrillators), or metallic implants in the treatment areas (dental implants not included.).

5. Subcutaneous fillers

6. Keloid scar

7. Patients with anticoagulant treatment plan.

8. Children, pregnant women, breastfeeding women.

9. Patients with the following disease conditions: bleeding disorders or coagulation disorder that may affect wound healing, active localized disease, herpes simplex, autoimmune diseases, diabetes, epilepsy bell-type paralysis (temporary facial palsy)

Related Conditions & MeSH terms

• Cutis Laxa
• Facial Skin Laxity

Intervention

Device:
• Microfocused ultrasound with visualization
Each subject to receive a minimum of 800 treatment lines, on two planes of treatment using the 4-4.5mm and 7-3.0mm transducer depths

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ulthera, Inc

References & Publications (1)

Lu PH, Yang CH, Chang YC. Quantitative Analysis of Face and Neck Skin Tightening by Microfocused Ultrasound With Visualization in Asians. Dermatol Surg. 2017 Nov;43(11):1332-1338. doi: 10.1097/DSS.0000000000001181. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Improvement in Skin Laxity in Submental Region and Neck at Day 90	Lift improvement as measured by quantitative analysis was considered greater than or equal to (>=) 20.0 square millimeter (mm^2) of the submental area Day 90 photograph compared to baseline photograph. The quantitative analysis was calculated by using five evenly spaced points on the neck. Area was calculated in between each of the 5 points and then sum of the five calculations was the total area of the region of interest.	Baseline, Day 90
Primary	Number of Participants With Lift in Brow Region at Day 90	Lift improvement as measured by quantitative analysis was considered minimum 0.5 millimeter (mm) Day 90 photograph compared to baseline photograph. The quantitative analysis was calculated by using five evenly spaced points along the natural outline of each participant's brow. Brow height was calculated using the sum and average of the five calculations in each brow area.	Baseline, Day 90
Secondary	Number of Participants With Overall Aesthetic Improvement as Assessed by the Principal Investigator Using the Global Aesthetic Improvement Scale (PGAIS) at Day 90	Overall aesthetic improvement was assessed by the principal investigator using global aesthetic improvement scale (GAIS). At 90 days post-treatment, each principal investigator completed a GAIS, known as physician global aesthetic improvement scale (PGAIS) .The GAIS is 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Only participants who had any improvement were reported.	Baseline, Day 90
Secondary	Number of Participants With Overall Aesthetic Improvement as Assessed by the Subject Global Aesthetic Improvement Scale (SGAIS) at Day 90	Overall aesthetic improvement was assessed by participants using global aesthetic improvement scale (GAIS). At 90 days post-treatment, each participant completed a GAIS, known as SGAIS.The GAIS is 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Only participants who had any improvement were reported.	Baseline, Day 90
Secondary	Number of Participants With Improvement in Patient Satisfaction Questionnaire at Day 90	Participants completed a PSQ at the 90-day visit. The PSQ has 5 satisfaction categories ranging from 'very dissatisfied' to 'very satisfied'.	Day 90
Secondary	Number of Participants With Overall Aesthetic Improvement as Assessed by the Physician Global Aesthetic Improvement Scale (PGAIS) at Day 180	Overall aesthetic improvement was assessed by the principal investigator using the GAIS. At 180 days post-treatment, each principal investigator completed a GAIS, known as PGAIS .The GAIS is 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Only participants who had any improvement were reported.	Baseline, Day 180
Secondary	Number of Participants With Overall Aesthetic Improvement as Assessed by the SGAIS at Day 180	Overall aesthetic improvement was assessed by participants using GAIS. At 180 days post-treatment, each participant completed a GAIS, known as SGAIS. The GAIS is 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Only participants who had any improvement were reported.	Baseline, Day 180